Various concepts involved in the quantification of radiation dose while following the theranostic approach in nuclear medicine are outlined. The availability of the relevant radionuclides is discussed. The production methodologies of many of the "matched-pair" of radionuclides were recently reviewed in detail. In this contribution, some additional information on a few positron emitters and therapeutic radionuclides is presented. In addition to generator production of 68 Ga (T ½ = 1.13 h), its direct production at a medical cyclotron is critically discussed. Besides conventional use of reactors and cyclotrons, there is a growing interest in utilizing fast neutrons from a d/Be source and high-energy photons from an electron linear accelerator to produce a few special therapeutic radionuclides. The related new developments are reviewed.
Introduction
Radioactivity is useful in nuclear medicine both for diagnosis and radiotherapy, provided suitable radionuclides are applied [1] . Diagnostic studies are generally carried out using γ-ray emitters or positron emitters, utilizing Single Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography (PET), respectively. For internal radiotherapy (endoradiotherapy), on the other hand, radionuclides emitting low-range highly ionizing radiation, i.e. α-or β − -particles, conversion and/or Auger electrons are in demand. Over the last three decades efforts have been underway in several laboratories to combine diagnosis (molecular imaging) with internal radionuclide therapy (molecular targeted treatment). This strategy is known today as the "theranostic approach". One of the major problems in internal radiotherapy, however, has been the quantification of individual radiation dose caused to various organs through the corpuscular radiation, mainly due to uncertainty in its measurement from outside of the body of the patient. In the theranostic approach, this difficulty is overcome through the combination of a suitable diagnostic radionuclide with the therapeutic radionuclide.
The basic condition of a theranostic application is that the same chemical compound is labelled with a diagnostic and a therapeutic radionuclide. The two radionuclides should preferably be of the same chemical element, although occasionally chemically analogous elements are also used. For diagnostic part of the investigation PET is ideal, but the use of SPECT is also increasing.
There are several suitable theranostic pairs of radionuclides. Their uses and production methods have been recently discussed in detail [2] . In the present review therefore only some newer aspects are treated, with some attention on production of a few special radionuclides using non-conventional nuclear reactions induced by high-energy photons or fast neutrons.
Theranostic concepts
Four concepts have been followed to quantify theranostic studies. They are discussed below.
(a) The initial approach was to use a γ-ray emitting surrogate of the therapeutic radionuclide. This involved a combination of a SPECT radionuclide of an element and a therapeutic radionuclide of a similar element. For example, 111 In (T ½ = 2.8 d), a trivalent metal, was utilized to quantify the therapeutic effect of 90 Y (T ½ = 2.7 d), another trivalent metal [3] . A monoclonal antibody (MAb) labelled with 111 In was used in therapy planning with 90 Y-MAb; the measurement of the radioactivity was based on SPECT. After many years of studies the procedure was recently abandoned because of some uncertainties. Several other surrogate metallic SPECT radionuclides were also considered at the Brookhaven National Laboratory in USA [4, 5] ; they proposed the term "theragnostic". However this concept did not provide the patient-individual quantitative data on radiation doses. (b) In a later approach the use of a pair of radionuclides of a particular chemical element, one a β + -emitter and the other a therapeutic radionuclide, was considered. The application of such a "matched-pair" of radionuclides was first attempted at the Forschungszentrum Jülich in Germany in the early 1990s. It was realized that for such a study a non-standard longer lived β + -emitter would be needed. Since the β + -emitting radionuclide 86 Y (T ½ = 14.7 h) had been developed and produced on a clinical scale [6, 7] , it was applied together with the β − -emitting radionuclide 90 Y (T ½ = 2.7 d), both in the form of citrate, in a tumour patient study [8] using PET. This allowed quantification of the longterm uptake kinetics of the therapeutic radionuclide and led to the ultimate desired parameter, i.e. radiation dose in mGy per MBq of the injected 90 Y activity. That study is regarded today as the stepping stone of the real theranostic approach. Further development of this concept has been described in detail [9] . This approach is referred to as "personalised medicine" because it involves the use of methods and products tailored to any individual patient [9] . (c) A more recent concept involves the use of a β + -emitting radionuclide in combination with the therapeutic radionuclide of a chemically analogous element [10] [11] [12] [13] . A prominent example is the pair 68 Ga (T ½ = 1.13 h)/ 177g Lu (T ½ = 6.4 d), the former being a β + -emitter and the latter a β − -emitting therapeutic radionuclide. There may be some difficulties in the pharmacology of the two differently-radiolabelled compounds which, however, could be corrected [cf. 9]. Due to rather easy availability of 68 Ga via a 68 Ge/ 68 Ga generator system and of 177g Lu through reactor production, combined with the recent successes in labelling a number of small peptides with trivalent metals, the pair 68 Ga/ 177g Lu is gaining very strong significance in tumour therapy.
However, the short half-life of 68 Ga in comparison to that of 177g Lu introduces some uncertainties in the quantification of the dose. The use of some longer lived β + -emitting analogue, e.g. 44g Sc (T ½ = 3.9 h) or 86 Y (T ½ = 14.7 h), may be more advantageous. Nonetheless, this concept appears very promising and further studies are continuing. (d) The most recent concept stipulates the use of a solitary radionuclide, emitting both a therapeutic radiation and an intense low-energy γ-ray which could be used for SPECT measurements to deliver dosimetric data. Two fast developing examples are 47 Sc (T ½ = 3.35 d) and 67 Cu (T ½ = 2.58 d) [cf. 14] . Chemically speaking, the diagnostic and therapeutic versions of the radiopharmaceutical are the same, and so the basic requirement of "personalised medicine" is met. However, from the radiation dosimetry point of view, there are two shortcomings: firstly, despite all progress the SPECT measurement is still not quantitative; secondly, the use of a long-lived therapeutic radionuclide for diagnostic imaging is questionable, unless a real therapy is planned. Worth pointing out here are the radionuclides 67 Ga (T ½ = 3.26 d) and 111 In (T ½ = 2.8 d) whose diagnostic use has been declining due to associated relatively high doses. Nonetheless, the concept of using a solitary radionuclide as a theranostic agent is presently attracting considerable interest.
The above given overview of various theranostic concepts suggests that the initial approach of using a γ-ray emitting surrogate of a therapeutic radionuclide is no more adequate. From quantitative dosimetry point of view the use of a β +emitter is very advantageous, be it a radionuclide of a chemical analogue or a radionuclide of the same chemical element as the therapeutic radionuclide. The concept of using a solitary radionuclide as a theranostic agent is chemically sound but considerable efforts would be needed to improve the radiation dosimetry.
Availability of theranostic radionuclides
Many of the β − -emitting therapeutic radionuclides now being considered under theranostic approach, e.g. 89 Sr (T ½ = 50.5 d), 90 Y (T ½ = 2.7 d), 131 I (T ½ = 8.02 d), 161 Tb (T ½ = 6.9 d), 177g Lu (T ½ = 6.4 d), etc. are routinely produced using nuclear reactors. In a few other cases, however, e.g. 47 Sc (T ½ = 3.35 d), 67 Cu (T ½ = 2.58 d) and 186 Re (T ½ = 3.78 d), which are presently getting strong attention for use as solitary theranostic agents, reactor production does not meet the necessary purity requirement. Efforts are therefore underway to produce them using other irradiation technologies. Similarly a few therapeutic radionuclides emitting 1 3
Auger electrons (e.g. 195m Pt: T ½ = 4.33 d), conversion electrons (e.g. 117m Sn: T ½ = 13.6 d) or α-particles (e.g. 225 Ac: T ½ = 10.0 d) are also not readily available. Their production methods are being developed.
With regard to β + -emitting radionuclides, it should be pointed out that the four cyclotron produced shortlived standard positron emitters of organic elements ( 11 C: T ½ = 20.4 min; 13 N: T ½ = 10.0 min; 15 O: T ½ = 2.0 min and 18 F: 109.8 min), commonly used in routine patient care studies via PET, are not suitable for theranostic applications. For those applications, generally longer lived non-standard β +emitters are needed which are also produced at cyclotrons. As mentioned in the Introduction, recently a detailed discussion was presented [2] , dealing with seven rather established "matched-pair" of radionuclides, namely 44g Sc/ 47 Sc, 64 Cu/ 67 Cu, 83 Sr/ 89 Sr, 86 Y/ 90 Y, 124 I/ 131 I and 152 Tb/ 161 Tb, which appear to be ideal for theranostic applications. Among the relevant positron emitters, 44g Sc, 64 Cu, 86 Y and 124 I are produced at low-energy cyclotrons. The production methodologies for the latter three radionuclides have been well developed and they are now more or less commercially available. With regard to 44g Sc, clinically relevant quantities have been produced using the 44 Ca(p,n) 44g Sc reaction as well as via the 44 Ti/ 44g Sc generator route. Further development work is, however, necessary to make this radionuclide generally available. The other two positron emitters, namely 83 Sr and 152 Tb, are still under development and need high energy cyclotrons to produce them. A summary of the status of production and availability of the "matched-pair" of radionuclides is given in Table 1 .
Regarding the theranostic concept involving a β + -emitter and an analogous element, the β + -emitter 68 Ga is now being extensively used in combination with the β − -emitter 177g Lu (as mentioned above). The radionuclide 68 Ga is commonly available through the above mentioned 68 Ge/ 68 Ga generator system, and 177g Lu is commercially available.
Thus in summary, several theranostic pairs of radionuclides are available for patient care studies or clinical research. Nevertheless, extensive work is still necessary to bring many other radionuclides to the level of clinical scale production.
New developments in production methodologies
In recent years the production methodologies of non-standard β + -emitters and novel therapeutic radionuclides have been extensively reviewed [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , with special emphasis on nuclear data [15, [19] [20] [21] [22] [23] [24] , radiochemical aspects [15] [16] [17] [18] [19] 25] and clinical scale production [15] [16] [17] [18] [19] 25] . The "matchedpair" of radionuclides were specifically discussed [2] . In the present review therefore only a few additional theranostic radionuclides are considered. They include the positron emitters 61 Cu and 68 Ga, and a few therapeutic radionuclides. A discussion of the newer production methodologies is given.
Positron emitters

61
Cu (T ½ = 3.3 h; E β + = 1.215 MeV; I β + = 62.0%)
This short-lived positron-emitting copper radionuclide is occasionally considered as an alternative to 64 Cu because it can be applied in smaller doses. However, the resolution of PET scans with 61 Cu is not as high as with 64 Cu due to the additional γ-rays and the higher positron endpoint energy of 61 Cu. Nonetheless, it has recently attracted some interest in a few laboratories. A large number of nuclear reactions have been investigated to produce 61 Cu. They include proton and deuteron induced reactions on isotopes of nickel and zinc as well as 3 He-and α-particle induced reactions on cobalt (for references to reaction cross section data cf. [15, 22, 23, 26, 27] ). Based on a critical evaluation of all reactions [26, 27] , Aslam and Qaim [27] presented a comparison of the major production routes of this radionuclide. The results are reproduced in Table 2 . The calculated yields for the reactions 61 Cu and 68 Zn(p,α) 61 Cu are in agreement within 5% uncertainty with the results from a recent evaluation by Tárkányi et al. [23] . For the 60 Ni(d,n) 61 Cu reaction, however, the yield value given in Table 2 is about twice that of the value given in Ref. [23] . This author considers the value by Tárkányi et al. [23] as wrong because their evaluated curve is too empirical beyond 7 MeV, having ignored some experimental data points up to 13 MeV.
As far as clinical scale production of 61 Cu is concerned, three routes, namely 61 Ni(p,n) 61 Cu, 64 Zn(p,α) 61 Cu and 59 Co(α,2n) 61 Cu have been developed. The 61 Ni(p,n) 61 Cu route is well established [28, 29] because the production methodology is the same as for 64 Cu, except that the target used is highly enriched 61 Ni instead of 64 Ni. Using this method GBq quantities of 61 Cu have been produced.
The production of 61 Cu via the 64 Zn(p,α) 61 Cu reaction also demands the use of highly enriched 64 Zn as target material (or to limit the proton energy to 12 MeV) to be able to achieve the desired quality of the product [30] . The electrolytic preparation of the target is similar to that for the production of radiogallium from zinc targets. The radiochemical separation of 61 Cu is achieved through ion-exchange chromatography. In a typical production run with 16 MeV protons on 99.3% enriched 64 Zn, the batch yield of 61 Cu amounted to about 1.5 GBq [31] , with good radionuclidic purity and high specific activity. In another work, 61 Cu was produced using 11.7 MeV protons on both nat Zn and 99.3% enriched 64 Zn as target materials [32] . After selective chemical separations 61 Cu of radiopharmaceutical quality was obtained from both targets; its batch yield from the enriched target amounted to about 0.7 GBq [32] .
The 59 Co(α,2n) 61 Cu reaction for the production of 61 Cu is used if the α-particle beam of about 40 MeV is available. The natural target material is a monoisotopic metal which can withstand high beam currents. The irradiated target is dissolved in HNO 3 and separation of 61 Cu is effected either by a combination of cation-and anion-exchange chromatography or by using a chelating resin [33, 34] . In a typical production experiment the batch yield of 61 Cu amounted to about 1.5 GBq [33] with 99.3% radionuclidic purity and good specific activity. By virtue of its suitable decay properties for PET imaging, combined with the increasing availability of 68 Galabelled compounds for molecular imaging, especially for tumour diagnostics, the significance of this radionuclide has increased considerably. Furthermore, it finds application in theranostics, both as a "matched-pair" with 67 Ga (an Auger electron emitter) and as an analogue of 177g Lu (a β − emitter) as described above. Efforts to produce this radionuclide have therefore been intensified in recent years. As mentioned above, this radionuclide is generally obtained via the 68 Ge/ 68 Ga generator system. The parent radionuclide 68 Ge (T ½ = 270.95 d) is produced through the nat Ga(p,xn)-process over the energy range E p = 70 → 20 MeV and radiogermanium is chemically extracted as GeCl 4 in toluene, benzene, etc. Further purification of 68 Ge is performed by several extraction and back-extraction cycles. For the preparation of the 68 Ge/ 68 Ga generator, the separated 68 Ge is loaded on a column filled with tin oxide, titanium oxide or an organic resin, and the daughter 68 Ga is periodically eluted with 0.01-1 M HCl [35, 36] . Optimisation studies have led to a very efficient processing of the 68 Gaeluate for medical application [35] . The 68 Ge/ 68 Ga generator is now commercially available and can nominally deliver up to 1.85 GBq of 68 Ga per elution. The eluted 68 Ga activity, however, decreases over time due to the decay of the parent radionuclide 68 Ge.
Direct production of 68 Ga
Thoughts have been developing in recent years to produce 68 Ga directly at a medical cyclotron. This strategy has emerged on the basis of two considerations: (1) the expense and uncertainty associated with the regular supply of the 68 Ge/ 68 Ga generator, (2) the current boom in the installation of medical cyclotrons (E p ≤ 18 MeV; E d ≤ 9 MeV) in almost all parts of the world [37] . Appreciable efforts have therefore already been devoted to development of direct production routes of 68 Ga, and a short summary is given below.
Among the various investigated processes, two routes appeared to be very promising:
(a) 68 Zn(p,n) 68 Ga. (b) 65 Cu(α,n) 68 Ga. In a detailed comparative study of the two reactions involving cross section measurements and yield calculations for various enrichments of the two target nuclei, namely 68 Zn and 65 Cu, Szelecsényi et al. [38] came to the conclusion that for production of 68 Ga via these two reactions, in both cases use of highly enriched targets is absolutely necessary to meet the radionuclidic purity demands on 68 Ga for medical use.
As regards proton induced nuclear reactions on 68 Zn, extensive experimental cross section measurements and evaluations were reported [39] . Later a further evaluation was done under the auspices of the IAEA [40] with the main focus on the reaction 68 Zn(p,2n) 67 Ga for the production of 67 Ga which was originally used in SPECT studies, but is now of interest in Auger therapy. In the meantime interest has arisen in the 68 Zn(p,n) 68 Ga reaction. A new evaluation lists all the references and presents a recommended curve [23] . A more systematic and critical evaluation of the three major reactions induced by protons up to 50 MeV on 68 Zn, leading to the formation of 68 Ga, 67 Ga and 66 Ga, was performed by Aslam et al. [41] , and the recommended cross sections are shown as smooth curves in Fig. 1 . From those data a suitable energy range for the production of 68 Ga via the 68 Zn(p,n) reaction was deduced to be E p = 14 → 5 MeV, its thick target yield amounting to about 8 GBq/µAh (for an irradiation time of 1 h) and the 67 Ga impurity to 0.12%. This impurity level can be further suppressed if the incident proton energy is kept below 13 MeV. The calculated 68 Ga yield values from the two evaluated curves [23, 41] agree within about 3%.
With regard to the 65 Cu(α,n) 68 Ga reaction for the production of 68 Ga, new cross section measurements have been reported in recent years. A comparison of those data with nuclear model calculations was presented [42] and an evaluation has also been performed [23] . From those data the optimum energy range for the production 68 Ga is deduced to be E α = 20 → 10 MeV, the thick target yield of the 68 Ga amounting to ~ 400 MBq/µAh (for an irradiation time of 1 h) [23] . In order to avoid the radionuclidic impurities, the incident α-particle energy should not exceed 20 MeV; the major impurity 67 Ga then amounts to 0.42% [38] .
As regards the practical production of 68 Ga, the first investigation on the route 68 Zn(p,n) 68 Ga was reported by Sadeghi et al. [43] using 97% enriched 68 Zn electroplated on copper as target material. After a 0.25 h irradiation with 15 MeV protons at a grazing angle of 6° and a beam current of 150 µA, radiogallium was separated by a combination of cation-exchange chromatography and solvent extraction. The batch yield of 68 Ga amounted to 190 GBq and the level of the 67 Ga impurity was found to be ≤ 0.01%. Production of tracer quantities of pure 68 Ga was also reported in irradiations of nat Zn targets with protons of energy < 7 MeV [44, 45] . Clinical scale production of pharmaceutical quality 68 Ga has recently been established by using a 99% enriched 68 Zn target and extensive chemical processing. The nominal batch yield is about 60 GBq [46] .
Besides the use of solid targetry to produce 68 Ga via the 68 Zn(p,n) reaction, considerable effort has been devoted in recent years to develop liquid targetry at small-sized medical cyclotrons. The constraint of low proton energy and the non-availability of extracted focussed beam to irradiate a small-sized highly enriched solid target served as impetus to that development. Thus solutions of several compounds of enriched 68 Zn have been irradiated, e.g. [ 68 Zn]ZnCl 2 [47, 48] , [ 68 Zn]Zn(NO 3 ) 2 [49] [50] [51] , etc. in pressurized targets made generally of niobium. Following extensive chemical separations the radionuclide 68 Ga is obtained in radiopharmaceutical quality. Care has, however, to be taken to remove also the radiation induced chemical species [51] . The batch yield of 68 Ga is much lower than that obtained via the solid targetry. Nonetheless, production yields of 68 Ga of up to 10 GBq have been reported [50, 51] which are sufficient for local use.
In contrast to the 68 Zn(p,n) 68 Ga reaction for the direct production of 68 Ga, which has been technically developed to produce clinically relevant quantities of 68 Ga of high specific activity, the 65 Cu(α,n) 68 Ga process has not received much attention beyond nuclear reaction cross section measurements, chemical separations of radiogallium and radiozinc from nat Cu irradiated with α-particles [52, 53] . On the other hand, tracer quantities of 66 Ga [54] and GBq amounts of 67 Ga [55] were produced via α-particle induced reactions on nat Cu.
In summary, the production of 68 Ga still follows mainly the 68 Ge/ 68 Ga generator route. At a few PET centres equipped with small medical cyclotrons, however, the Fig. 1 Excitation functions of proton induced nuclear reactions on 68 Zn leading to the formation of the radionuclides 68 Ga, 67 Ga and 66 Ga. Plots are based on evaluated data reported by Aslam et al. [41] . A suitable energy range for the production of 68 Ga is E p = 14 → 5 MeV direct production route, namely the 68 Zn(p,n) 68 Ga reaction on a highly enriched target, is also finding increasing use. In the latter case, though both solid and liquid targetry have been developed, the use of a solution target is gaining more acceptance. The 68 Ga batch yield via a solution target amounts to about 10 GBq and corresponds to approximately 15% of the nominal yield through a solid target. This yield is adequate for local use. There is some scepticism about the purity and radiopharmaceutical quality of the directly produced 68 Ga, apart from the higher local effort involved in the production than in the elution from an available 68 Ge/ 68 Ga generator system. Nonetheless, some reports claim that the quality of the directly produced 68 Ga is excellent and the PET centre is independent of the supply of the commercial generator. Furthermore, since the batch yield of 68 Ga via the 68 Zn(p,n)-reaction is much higher than that per elution from a nominal 68 Ge/ 68 Ga generator, 68 Ga-labelled compounds of higher specific activity could be obtained using the directly produced 68 Ga. However, more detailed studies are called for to substantiate those claims.
Therapeutic radionuclides
Out of a large number of therapeutic radionuclides of potential interest in theranostic applications, the radionuclides 47 Sc, 67 Cu, 117m Sn, 186 Re and 225 Ac are presently of great interest. The radionuclides 47 Sc (T ½ = 3.35 d), 67 Cu (T ½ = 2.58 d) and 186 Re (T ½ = 3.78 d) are low-energy β −emitters, 117m Sn (T ½ = 13.6 d) is unique because it is a conversion electron emitter and 225 Ac (T ½ = 10.0 d) is an α-particle emitter. The first four of them emit also a γ-ray suitable for SPECT studies; they are thus considered as solitary theranostic radionuclides. This is in addition to the use of the radionuclides 47 Sc and 67 Cu as matched-pairs with their corresponding positron emitters 44g Sc and 64 Cu, respectively. The radionuclide 225 Ac is in great demand and finds application in α-targeted therapy, whereby the dose quantification is done by using the analogue positron emitting radionuclide 68 Ga.
As far as the production methodologies are concerned, a recent review [18] summarizes the available information on 186 Re and 117m Sn, and another review discusses the various routes of production of 225 Ac and a few other potentially interesting α-particle emitters [24] . The production methods for 47 Sc and 67 Cu have also been critically analysed [2] . In this section, therefore, only two new developing approaches for the production of the latter two radionuclides are discussed.
Use of high-energy photons from LINAC
The use of electron linear accelerator (LINAC) to deliver high-energy photons for production of 47 Sc, 67 Cu and a few other β − -emitting radionuclides is presently under very much discussion. A 40 MeV electron beam from the accelerator falling on a heavy metal target (e.g. tungsten) delivers photons with an energy spectrum extending from about 0.1-40 MeV (see Fig. 2 , taken from [56] ). In the same diagram the excitation functions of the 48 Ti(γ,p) 47 Sc and 68 Zn(γ,p) 67 Cu reactions, taken from [57] , are also shown. Obviously the photon spectrum is suitable for the production of both 47 Sc and 67 Cu, but the cross sections are rather low. Since the strength of the present day photon sources is also generally low, it is presently not possible to produce those radionuclides in quantities sufficient for medical application. On the other hand, the accelerator technology is well established and it is expected that high power facilities could be developed. This would compensate for the low cross section and would boost up the batch yield.
Some experimental studies on the production of 47 Sc via the 48 Ti(γ,p) 47 Sc reaction have been going on for some time [58] [59] [60] . Very recently this radionuclide has been produced via this route at the Argonne National Laboratory in batch yields of about 185 MBq [60] . With regard to the 68 Zn(γ,p) 67 Cu reaction for the production of 67 Cu, several studies have been performed over the last 40 years [cf. 58, 59, [61] [62] [63] [64] [65] [66] . Although high-purity product was obtained, the batch yield of 67 Cu was limited to a few tens of MBq. A very recent preliminary report from the Argonne National Laboratory [67] , however, indicates that using the upgraded 25 kW power LINAC about 8 GBq of 67 Cu can now be produced, with possibilities of further improvement. Nevertheless, it should be pointed out that the chemical processing of bulky targets is rather cumbersome, especially in view of the stringent demand regarding the chemical purity and specific activity of the desired product. [56] . Also shown are the excitation functions of the reactions 48 Ti(γ,p) 47 Sc and 68 Zn(γ,p) 67 Cu, taken from Ref. [57] Several other medically interesting radionuclides which could possibly also be produced via photonuclear reactions were listed earlier [22] . Among them, thoughts are developing on the use of a LINAC to produce 99 Mo (the parent of 99m Tc) via the 100 Mo(γ,n) 99 Mo reaction as a substitute to the reactor production. Similarly, the production of the α-emitter 225 Ac via the route 226 Ra(γ,n) 225 Ra β − 14.8 d 225 Ac is also being considered. The cross sections of the (γ,n) reactions are much higher than those of the (γ,p) reactions used for the production of 47 Sc and 67 Cu, so that the expected yields of both 99 Mo and 225 Ra could be quite high. However, the problem of processing a bulky target will remain.
Use of fast neutrons from accelerators
The fast component of the neutron spectrum of a fission reactor has been often used to produce a few therapeutic radionuclides via the (n,p) reaction, e.g. 32 P, 35 S, 89 Sr, etc. Over the last few years, however, ideas have been emerging to utilize the fast neutrons generated at accelerators/ cyclotrons in radionuclide production. Three concepts are developing: With regard to the use of quasi-monoenergetic neutrons, tracer amounts of 67 Cu were produced via the 67 Zn(n,p) 67 Cu reaction using low-intensity 14 MeV neutrons available at a DT-neutron generator [65, 68] . However, the presently available technology is not adequate for clinical scale production.
As regards the use of deuteron breakup neutrons, cross section measurements on (n,p) reactions using a 14 MeV d/Be neutron source revealed that the yield of the product radionuclide is at least three times higher than that using a nuclear reactor [69, 70] . Extensive work has been done at the Forschungszentrum Jülich on the characterisation of d(Be) breakup neutrons and their use in nuclear reaction cross section measurements [cf. [71] [72] [73] [74] [75] [76] as well as integral tests of differential data [cf. 70, 76] . The 30 MeV d(Be) neutron spectrum measured in the 0° direction [cf. 73] is shown in Fig. 3 . Also shown in Fig. 3 are the excitation functions of 67 Zn(n,p) 67 Cu and 68 Zn(n,d + nʹp) 67 Cu reactions taken from TENDL-2017 [77] . They should serve as approximations because the experimentally available data for the 67 Zn(n,p) 67 Cu reaction are discrepant [cf. 70] and for the 68 Zn(n,d + nʹp) 67 Cu reaction only one value at 14.7 MeV is available [78] . Nonetheless, it can be concluded that the neutron spectrum shown in Fig. 3 is quite suitable for the production of 67 Cu via the above mentioned two processes. The cross section of the 68 Zn(n,d + nʹp) 67 Cu reaction is higher. However, its cross section averaged for the neutron spectrum given in Fig. 3 amounts only to 60 ± 5% of the averaged cross section for the 67 Zn(n,p) 67 Cu reaction. This is due to the rather low intensity of neutrons above 20 MeV. The ratio of the two averaged cross sections may be compared with a value derived in a somewhat different way. A large number of integral cross section measurements using a 30 MeV d(Be) neutron spectrum were carried out [81] in our laboratory already in 1980 and, based on the results, some systematic trends were established for the (n,2n), (n,p), (n,d + nʹp) and (n,α) reactions. From those systematics the integral cross sections for the 67 Zn(n,p) 67 Cu and 68 Zn(n,d + nʹp) 67 Cu reactions are deduced to be 13 ± 2.5 mb and 9 ± 2 mb, respectively. The value for the latter reaction [73] . Also shown are the excitation functions of the reactions 67 Zn(n,p) 67 Cu and 68 Zn(n,d + nʹp) 67 Cu, taken from TENDL-2017 [77] thus corresponds to 69 ± 10% of the integral cross section for the 67 Zn(n,p) 67 Cu reaction. The presently derived value of 60 ± 5% is thus in agreement (within the uncertainty limits) with the value obtained from the systematics. The results suggest that the cross sections of both the reactions are high enough to produce 67 Cu in sufficient quantity, provided a high-flux neutron source is available and clean chemical separations can be performed. The 68 Zn(n,d + nʹp) 67 Cu reaction may be more suitable if a 40 MeV d(Be) neutron source is used. This was actually demonstrated recently by a Japanese group. In a few studies using fast neutrons from 40 MeV deuteron breakup on a graphite target, 67 Cu was produced via the 68 Zn(n,d + nʹp) 67 Cu reaction on a 99.3% enriched 68 ZnO target [79, 80] . The product was shown to be suitable for preclinical studies [80] . For large scale production, however, further extensive development work using high neutron fluxes is needed. It should also be pointed out that irradiations of various target elements with fast deuteron breakup neutrons also generate considerable amount of tritium via (n,xt) reactions, with cross sections of a few mb [cf. 81]. Special attention must therefore be given to tritium removal while chemically processing the irradiated material.
With regard to possible use of spallation neutrons for production of therapeutic radionuclides, feasibility studies [cf. 82] and critical discussions [cf. 22] are in progress. Spallation-neutron induced (n,xp) reactions have some potential for production of a few therapeutic radionuclides, but large efforts are needed to develop the relevant high-intensity neutron sources.
As regards a white neutron source, intense flux is available at a powerful LINAC. The energies are, however, in the low energy range. That source could be used to induce the (n,γ) reaction, e.g. for the production of 99 Mo via the 98 Mo(n,γ) 99 Mo process. Some therapeutic radionuclides could also be produced via the (n,γ) route. Several laboratories are planning to make use of such a source in radionuclide production but so far any practical application has not been demonstrated.
Conclusion
The theranostic approach in nuclear medicine holds great promise because it is regarded as personalised medicine. Its future success will, however, depend on the availability of suitable radionuclides and the organometallic compounds prepared using them. Regarding the radionuclides, production technology is now sufficiently advanced to supply most of the established non-standard positron emitters, and work on other potentially useful positron emitters in continuing. Several of the therapeutic radionuclides are also available for clinical use. Nonetheless, tremendous efforts are being harnessed today to produce many more theranostic radionuclides, and new technologies are being developed. The future of radionuclide production technology thus appears to be very bright. Because of stringent purity demands on metallic radionuclides, however, the significance of analytical radiochemistry cannot be overemphasized.
